EU Pay-For-Delay Ruling Against Lundbeck Sends Signal To Others, Including UK Competition Body
Executive Summary
The EU’s General Court has upheld the European Commission’s decision to fine Lundbeck and a number of generics firms for agreeing to keep generic versions of the antidepressant citalopram off the market in return for payments. The ruling could have implications for other similar cases such as that involving GlaxoSmithKline’s paroxetine in the UK.
You may also be interested in...
EU’s Top Court Upholds Lundbeck Fines Over Pay-For-Delay Deals
The CJEU found no error in a near decade-old decision by the European Commission that Lundbeck conspired with generic manufacturers to unlawfully delay competition to its antidepressant Celexa (citalopram).
CJEU Opinion Backs Lundbeck Fine Over Citalopram ‘Pay For Delay’ Deals
A CJEU advocate general has backed a European Commission fine of almost €94m imposed on Lundbeck over “pay for delay” deals struck with four generics firms over citalopram.
UK Wants European Court's View On Paroxetine Pay-For-Delay Case
A referral in the long-running paroxetine pay-for-delay case will see the Court of Justice of the EU give preliminary rulings on a number of competition issues such as abuse of a dominant position, the relevant product market, and restrictions of competition by object and by effect.